Analystreport

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its price target raised by analysts at B. Riley from $194.00 to $236.00. They now have a "neutral" rating on the stock.

Madrigal Pharmaceuticals, Inc.  (MDGL) 
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am Check Earnings Report
US:NASDAQ Investor Relations: madrigalpharma.com